|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fan L, Strasser-Weippl K, Li JJ, St Louis
J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM and Goss PE: Breast
cancer in China. Lancet Oncol. 15:e279–e289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jia X, Liu G, Cheng J, Shen Z and Shao Z:
CYR61 contributes to poor response to letrozole in ER positive
breast carcinoma. Curr Cancer Drug Targets. 2016.
|
|
5
|
Masood S: Estrogen and progesterone
receptors in cytology: A comprehensive review. Diagn Cytopathol.
8:475–491. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bross PF, Baird A, Chen G, Jee JM,
Lostritto RT, Morse DE, Rosario LA, Williams GM, Yang P, Rahman A,
et al: Fulvestrant in postmenopausal women with advanced breast
cancer. Clin Cancer Res. 9:4309–4317. 2003.PubMed/NCBI
|
|
7
|
Ciruelos E, Pascual T, Arroyo Vozmediano
ML, Blanco M, Manso L, Parrilla L, Muñoz C, Vega E, Calderón MJ,
Sancho B and Cortes-Funes H: The therapeutic role of fulvestrant in
the management of patients with hormone receptor-positive breast
cancer. Breast. 23:201–208. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Polascik TJ and Mouraviev V: Zoledronic
acid in the management of metastatic bone disease. Ther Clin Risk
Manag. 4:261–268. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Russell RG: Bisphosphonates: Mode of
action and pharmacology. Pediatrics. 119 Suppl 2:S150–S162. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mundy GR: Metastasis to bone: Causes,
consequences and therapeutic opportunities. Nat Rev Cancer.
2:584–593. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fromigue O, Lagneaux L and Body JJ:
Bisphosphonates induce breast cancer cell death in vitro. J Bone
Miner Res. 15:2211–2221. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jagdev SP, Coleman RE, Shipman CM, Rostami
HA and Croucher PI: The bisphosphonate, zoledronic acid, induces
apoptosis of breast cancer cells: Evidence for synergy with
paclitaxel. Br J Cancer. 84:1126–1134. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Virtanen SS, Väänänen HK, Härkönen PL and
Lakkakorpi PT: Alendronate inhibits invasion of PC-3 prostate
cancer cells by affecting the mevalonate pathway. Cancer Res.
62:2708–2714. 2002.PubMed/NCBI
|
|
14
|
Boissier S, Ferreras M, Peyruchaud O,
Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaissé JM and
Clézardin P: Bisphosphonates inhibit breast and prostate carcinoma
cell invasion, an early event in the formation of bone metastases.
Cancer Res. 60:2949–2954. 2000.PubMed/NCBI
|
|
15
|
Fournier P, Boissier S, Filleur S,
Guglielmi J, Cabon F, Colombel M and Clézardin P: Bisphosphonates
inhibit angiogenesis in vitro and testosterone-stimulated vascular
regrowth in the ventral prostate in castrated rats. Cancer Res.
62:6538–6544. 2002.PubMed/NCBI
|
|
16
|
Wood J, Bonjean K, Ruetz S, Bellahcène A,
Devy L, Foidart JM, Castronovo V and Green JR: Novel antiangiogenic
effects of the bisphosphonate compound zoledronic acid. J Pharmacol
Exp Ther. 302:1055–1061. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cheng J, Lei L, Xu J, Sun Y, Zhang Y, Wang
X, Pan L, Shao Z, Zhang Y and Liu G: 18F-fluoromisonidazole PET/CT:
A potential tool for predicting primary endocrine therapy
resistance in breast cancer. J Nucl Med. 54:333–340. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jia X, Hong Q, Lei L, Li D, Li J, Mo M,
Wang Y, Shao Z, Shen Z, Cheng J and Liu G: Basal and therapy-driven
hypoxia-inducible factor-1alpha confers resistance to endocrine
therapy in estrogen receptor-positive breast cancer. Oncotarget.
6:8648–8662. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang XM, Wang YS, Zhang J, Li Y, Xu JF,
Zhu J, Zhao W, Chu DK and Wiedemann P: Role of PI3K/Akt and MEK/ERK
in mediating hypoxia-induced expression of HIF-1alpha and VEGF in
laser-induced rat choroidal neovascularization. Invest Ophthalmol
Vis Sci. 50:1873–1879. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Aebersold DM, Burri P, Beer KT, Laissue J,
Djonov V, Greiner RH and Semenza GL: Expression of
hypoxia-inducible factor-1alpha: A novel predictive and prognostic
parameter in the radiotherapy of oropharyngeal cancer. Cancer Res.
61:2911–2916. 2001.PubMed/NCBI
|
|
21
|
Zhong H, De Marzo AM, Laughner E, Lim M,
Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL and Simons
JW: Overexpression of hypoxia-inducible factor 1alpha in common
human cancers and their metastases. Cancer Res. 59:5830–5835.
1999.PubMed/NCBI
|
|
22
|
Bachtiary B, Schindl M, Pötter R, Dreier
B, Knocke TH, Hainfellner JA, Horvat R and Birner P: Overexpression
of hypoxia-inducible factor 1alpha indicates diminished response to
radiotherapy and unfavorable prognosis in patients receiving
radical radiotherapy for cervical cancer. Clin Cancer Res.
9:2234–2240. 2003.PubMed/NCBI
|
|
23
|
Jiang HL, Sun HF, Gao SP, Li LD, Huang S,
Hu X, Liu S, Wu J, Shao ZM and Jin W: SSBP1 suppresses TGFβ-driven
epithelial-to-mesenchymal transition and metastasis in
triple-negative breast cancer by regulating mitochondrial
retrograde signaling. Cancer Res. 76:952–964. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jiang HL, Sun HF, Gao SP, Li LD, Hu X, Wu
J and Jin W: Loss of RAB1B promotes triple-negative breast cancer
metastasis by activating TGF-β/SMAD signaling. Oncotarget.
6:16352–16365. 2015.PubMed/NCBI
|
|
25
|
Senaratne SG, Pirianov G, Mansi JL, Arnett
TR and Colston KW: Bisphosphonates induce apoptosis in human breast
cancer cell lines. Br J Cancer. 82:1459–1468. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gnant M and Clézardin P: Direct and
indirect anticancer activity of bisphosphonates: A brief review of
published literature. Cancer Treat Rev. 38:407–415. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Clézardin P, Fournier P, Boissier S and
Peyruchaud O: In vitro and in vivo antitumor effects of
bisphosphonates. Curr Med Chem. 10:173–180. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ottewell PD, Mönkkönen H, Jones M, Lefley
DV, Coleman RE and Holen I: Antitumor effects of doxorubicin
followed by zoledronic acid in a mouse model of breast cancer. J
Natl Cancer Inst. 100:1167–1178. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Heymann D, Ory B, Blanchard F, Heymann MF,
Coipeau P, Charrier C, Couillaud S, Thiery JP, Gouin F and Redini
F: Enhanced tumor regression and tissue repair when zoledronic acid
is combined with ifosfamide in rat osteosarcoma. Bone. 37:74–86.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Moriceau G, Ory B, Mitrofan L, Riganti C,
Blanchard F, Brion R, Charrier C, Battaglia S, Pilet P, Denis MG,
et al: Zoledronic acid potentiates mTOR inhibition and abolishes
the resistance of osteosarcoma cells to RAD001 (Everolimus):
Pivotal role of the prenylation process. Cancer Res.
70:10329–10339. 2010. View Article : Google Scholar : PubMed/NCBI
|
